Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Gut|February 11, 2016
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidaseNikhil Vergis, Wafa Khamri, Kylie Beale, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 25, 2025
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025Glenn F Pierce, Margareth C Ozelo, Johnny Mahlangu, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Elife|September 4, 2019
Interferon lambda 4 impacts the genetic diversity of hepatitis C virusM Azim Ansari, Elihu Aranday-Cortes, Camilla Lc Ip, et al.
BMJ Open|November 18, 2020
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort studyAlvina G Lai, Laura Pasea, Amitava Banerjee, et al.
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Journal of Viral Hepatitis|March 12, 2022
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data setJake R Morgan, Elizabeth Marsh, Alexandra Savinkina, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Gut|February 11, 2016
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidaseNikhil Vergis, Wafa Khamri, Kylie Beale, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 25, 2025
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025Glenn F Pierce, Margareth C Ozelo, Johnny Mahlangu, et al.
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infectionNezam Afdhal, Stefan Zeuzem, Paul Kwo, et al.
Elife|September 4, 2019
Interferon lambda 4 impacts the genetic diversity of hepatitis C virusM Azim Ansari, Elihu Aranday-Cortes, Camilla Lc Ip, et al.
BMJ Open|November 18, 2020
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort studyAlvina G Lai, Laura Pasea, Amitava Banerjee, et al.
Journal of Hepatology|September 21, 2014
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJordan J Feld, Ira M Jacobson, Donald M Jensen, et al.
Journal of Viral Hepatitis|March 12, 2022
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data setJake R Morgan, Elizabeth Marsh, Alexandra Savinkina, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Gastroenterology|October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis BPatrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
Pageof 20